We found that the percentage of NCAMhiCD44lo/– tumors, defined with over 50% of cancer cells highly expressing NCAM and with low or no CD44 expression [37], increased with malignant progression and metastasis (Fig. 1B, Fig. S1A and Table S1). The gene discussed is CD44; the disease is cancer.